Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).

Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).

Item
http://www.wikidata.org/entity/Q38072094
Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β): candidate drug for preventing beta-cell apoptosis and diabetesDevelopment of Potent and Selective Inhibitors for Group VIA Calcium-Independent Phospholipase A2 Guided by Molecular Dynamics and Structure-Activity Relationships.Anti-inflammatory trends of new benzimidazole derivatives.Group X secreted phospholipase A(2) induces lipid droplet formation and prolongs breast cancer cell survival.New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2.Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis.The anti-inflammatory effects of Yunnan Baiyao are involved in regulation of the phospholipase A2/arachidonic acid metabolites pathways in acute inflammation rat model.Anti-inflammatory Activity of Magnesium Isoglycyrrhizinate Through Inhibition of Phospholipase A2/Arachidonic Acid Pathway.Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain.2-Oxoesters: A Novel Class of Potent and Selective Inhibitors of Cytosolic Group IVA Phospholipase A2.2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A2 inhibitors.A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.1-(5-Carboxyindazol-1-yl)propan-2-ones as dual inhibitors of cytosolic phospholipase A2α and fatty acid amide hydrolase: bioisosteric replacement of the carboxylic acid moiety.
P2860

Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).

Item
http://www.wikidata.org/entity/Q38072094
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Phospholipase A2 inhibitors fo ...... patent review (2010--present).
@en
type
label
Phospholipase A2 inhibitors fo ...... patent review (2010--present).
@en
prefLabel
Phospholipase A2 inhibitors fo ...... patent review (2010--present).
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Phospholipase A2 inhibitors fo ...... patent review (2010--present)
@en
P2093
P2860
P304
P31
P356
10.1517/13543776.2013.754425
P407
P433
P478
P50
P577
P698